These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18080023)

  • 1. [New advances in the treatment of chronic hepatitis B: position of entecavir].
    Olaso V
    Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
    Cheng PN; Chang TT
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Entecavir - options and obstacles of an effective treatment for chronic hepatitis B].
    Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2010 Jan; 135(1-2):32-7. PubMed ID: 20024882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 6. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir for the long-term treatment of chronic hepatitis B.
    Gonzalez SA; Keeffe EB
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1053-62. PubMed ID: 19883325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
    Zoulim F
    Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anti-hepatitis B virus drugs].
    Minami M
    Nihon Rinsho; 2012 Apr; 70(4):609-13. PubMed ID: 22568141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.
    Yao G
    J Antimicrob Chemother; 2007 Aug; 60(2):201-5. PubMed ID: 17556353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations.
    Tong CY; Mullen JE; Wong T
    J Antimicrob Chemother; 2009 Oct; 64(4):875-7. PubMed ID: 19671587
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
    Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
    J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Think twice if you consider entecavir treatment in cases with lamivudine refractoriness.
    Ustundag Y; Topalak O
    Hepatology; 2010 Jul; 52(1):397-8. PubMed ID: 20229575
    [No Abstract]   [Full Text] [Related]  

  • 15. Entecavir.
    Opio CK; Lee WM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Jul; 4(7):535-6. PubMed ID: 16075486
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir surprise.
    Hirsch MS
    N Engl J Med; 2007 Jun; 356(25):2641-3. PubMed ID: 17582076
    [No Abstract]   [Full Text] [Related]  

  • 18. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV.
    Jain MK; Zoellner CL
    AIDS; 2007 Nov; 21(17):2365-6. PubMed ID: 18090296
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
    Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
    Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
    [No Abstract]   [Full Text] [Related]  

  • 20. Entecavir for chronic hepatitis B: a review.
    Palumbo E
    Ther Drug Monit; 2008 Feb; 30(1):1-4. PubMed ID: 18223455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.